CSIMarket
 
Enzo Biochem Inc  (ENZ)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $1.2500 $0.04 3.306%
Day's High: $1.29 Week Perf: -1.57 %
Day's Low: $ 1.21 30 Day Perf: -7.41 %
Volume (M): 78 52 Wk High: $ 2.74
Volume (M$): $ 98 52 Wk Avg: $1.66
Open: $1.26 52 Wk Low: $1.16



 Market Capitalization (Millions $) 64
 Shares Outstanding (Millions) 51
 Employees 412
 Revenues (TTM) (Millions $) -19,628
 Net Income (TTM) (Millions $) 33
 Cash Flow (TTM) (Millions $) 54
 Capital Exp. (TTM) (Millions $) 3

Enzo Biochem Inc
Enzo Biochem Inc. is a global biotechnology company that specializes in the development and commercialization of innovative life science research tools, clinical diagnostic products, and therapeutic offerings. The company has been involved in the field of biomedical research for over 40 years and has established itself as a leading player in the industry.

The company operates through three main units: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. Enzo Life Sciences is dedicated to developing and providing a wide range of high-quality research reagents, assay kits, and platforms to enable scientists to better understand diseases and develop new treatments. The company's product portfolio includes more than 40,000 high-performance antibodies, proteins, peptides, and small molecules that are used in numerous research areas, including cancer, cardiovascular disease, neurodegeneration, infectious diseases, and genomics.

Enzo Clinical Labs is a full-service clinical laboratory that provides an array of advanced diagnostic testing services to physicians, patients, and hospitals across the U.S. The company specializes in testing for gastrointestinal, endocrine, and infectious diseases, as well as cancer, genetic disorders, and drug monitoring. Enzo Clinical Labs has received numerous accreditations and certifications from leading organizations, including the College of American Pathologists (CAP), CLIA, and the New York State Department of Health.

Enzo Therapeutics is focused on developing innovative therapeutic products for the treatment of cancer, autoimmune, and inflammatory disorders. The company has a pipeline of novel small molecules and biologics that target specific disease pathways and have the potential to provide more effective therapies with fewer side effects than traditional treatments.

Enzo Biochem has a strong intellectual property portfolio, with over 270 issued patents worldwide covering a wide range of technologies, including nucleic acid labeling, detection, and quantification, recombinant protein production, and monoclonal antibody-based products. The company has also formed strategic partnerships with leading academic and commercial organizations to develop new products and technologies.

Enzo Biochem has a diverse customer base ranging from academic researchers to biotech and pharmaceutical companies, clinical laboratories, and healthcare providers. The company has a global presence with operations in the U.S., Europe, and Asia and sells its products and services in more than 100 countries worldwide.

The company has a strong financial position, with revenues of $101 million in fiscal year 2020 and a net income of $2 million. The company has a market capitalization of approximately $118 million and is traded on the New York Stock Exchange under the ticker symbol ENZ.

In summary, Enzo Biochem Inc is a well-established and respected biotech company that is focused on developing and commercializing innovative life science research tools, clinical diagnostic products, and therapeutic offerings. With a strong product pipeline, intellectual property portfolio, and global presence, the company is well-positioned to continue to grow and succeed in the dynamic and competitive biotech industry.


   Company Address: 81 Executive Blvd New York 11735 NY
   Company Phone Number: 755-5500   Stock Exchange / Ticker: NYSE ENZ
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Enzo Biochem Inc

Enzo Biochem Inc Revenue Plummeted during November to January 31, 2024 Period

Enzo Biochem Inc, a medical laboratories company, experienced a stable stock performance in March 2024 with no change in its share price. However, this brings the share price to a decrease of 11.33% in the first quarter of 2024. Additionally, the stock is currently trading only 33% above its 52-week low.
For the financial second quarter of 2024, Enzo Biochem Inc reported a significant improvement in its earnings per share (EPS) compared to the previous year. The loss per share decreased from $-0.23 to $-0.06. Furthermore, the EPS also improved from the preceding quarter, going from $-0.13 to $-0.06.

Enzo Biochem Inc

Enzo Biochem Inc Reports Improved Performance with a Deficit of $-0.13 per Share in August to October 31, 2023 Period

As an avid investor and reader of the , I couldn't help but delve into the recent financial results of Enzo Biochem Inc. The numbers paint an interesting picture of the company's performance from August to October 31, 2023.
First and foremost, let's discuss the bottom line. Enzo Biochem reported a loss of $-0.13 per share during this time frame, an improvement from the loss of $-0.22 per share in the same reporting season a year before. It's always encouraging to see a reduction in losses, a sign that the company is heading in the right direction. Moreover, the EPS fell from $1,168.23 per share in the previous reporting season, which could raise concerns among shareholders.

Enzo Biochem Inc

Revised Headline: Enzo Biochem Inc Achieves Profitability Milestone with Strong Financial Performance in May to July 2023 Quarter

During the past week, Enzo Biochem Inc shares experienced a decline of -3.55%. This brings the year to date performance to -1.45%. Despite this recent decrease, Enzo Biochem Inc shares are still trading 36% above their 52-week low.
One significant development for Enzo Biochem Inc is the improvement in their financial performance. In the period from May to July 31, 2023, the company achieved a turnaround to profits. The earnings per share during this period stood at $1,168.23 per share, which is a positive shift compared to $-0.17 per share reported in the previous financial reporting period. In the same period a year ago, the company recorded a loss per share of $-0.31.
The net income for Enzo Biochem Inc in the May to July 31, 2023 period also demonstrated significant improvement, with a net income of $57.430 million, compared to a net deficit of $-8.433 million in the same period a year ago. This is an encouraging development for the company.

Enzo Biochem Inc

Enzo Biochem Inc. Faces Dramatic Revenue Decline: An Unforeseen Shortfall Revealed in FY 2023

Enzo Biochem Inc, a leading manufacturer and distributor of clinical diagnostic products and life science research tools, has reported significant losses in its third-quarter results for 2023.
According to the financial report, the company's shortfall per share increased to $-0.31 in the third quarter, compared to $-0.10 in the same period a year ago. This represents a massive 210 percent increase in losses, indicating a challenging market environment.






 

Enzo Biochem Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com